Janux Therapeutics, Inc.
Clinical-stage oncology biotech developing tumor-activated T-cell engagers, led by JANX007 in metastatic castration-resistant prostate cancer.
Oncology / prostate cancer · Tumor-activated T-cell engager immunotherapies · Phase 1b